INS and Insulin resistance: In addition, Ad-shAcrp30 treatment exhibited clinical signs of glucose and lipid abnormalities and insulin resistance with increased plasma insulin, FFA, TG, TC and LDL-C and decreased HDL-C levels (P<0.01 or P<0.05, Table 1).